04/28/2026
Long post, but Coenzyme Q10, 100-200mg taken daily for three months, enhances human egg quality, particularly in older eggs, and is especially helpful in IVF.
https://www.facebook.com/story.php?story_fbid=1882059669372262&id=100027047427020&post_id=100027047427020_1882059669372262&sfnsn=mo&mibextid=6aamW6
Egg quality declines with age. That part is familiar. What most coverage leaves out is the specific biochemical lesion that drives the decline, and it sits inside a pathway that's actually amenable to dietary intervention.
Human eggs are unusual cells. They are the largest cell in the body, they arrest in meiosis for decades before ovulation, and they contain more mitochondria than any other cell type in the body, roughly 100,000 per mature oocyte. Those mitochondria produce the ATP that powers meiotic resumption, spindle assembly, and the energetic demands of fertilization and early embryo development. An egg with dysfunctional mitochondria cannot execute meiosis cleanly, which is one reason aneuploidy rates rise sharply with maternal age.
Ben-Meir and colleagues (Aging Cell, 2015) identified a specific cause of that mitochondrial dysfunction. They examined oocytes from aged female mice and from older human IVF patients, and found that two enzymes responsible for endogenous coenzyme Q10 biosynthesis, Pdss2 and Coq6, were significantly downregulated in aged oocytes of both species. Coenzyme Q10 shuttles electrons between complex I and complex III of the mitochondrial electron transport chain; without sufficient CoQ10, the chain stalls, ATP production drops, and cellular function falters. Oocytes normally synthesize their own CoQ10, but aged oocytes lose this capacity. The group then deleted Pdss2 specifically in mouse oocytes and recapitulated the aging phenotype, including reduced ATP, meiotic spindle errors, and premature ovarian failure. Dietary CoQ10 administration reversed the phenotype in aged mice and prevented it in the Pdss2-deficient mice. The mechanism is not hypothetical. It's causal in the animal model, and the biochemical signature was directly confirmed in human oocytes.
The human clinical data lines up with the mechanism. Xu and colleagues (Reproductive Biology and Endocrinology, 2018) randomized 186 young women with diminished ovarian reserve to 60 days of CoQ10 pretreatment or no pretreatment before IVF-ICSI. Women in the CoQ10 group required lower gonadotropin doses, produced more oocytes, had higher fertilization rates, and produced more high-quality embryos. The most striking result was cycle cancellation: 8.3% in the CoQ10 group versus 22.9% in controls. Clinical pregnancy and live birth rates trended in favor of CoQ10 but did not reach statistical significance in that single trial.
Two recent systematic reviews pooled the available data. Lin and colleagues (Annals of Medicine, 2024) included six randomized trials with 1,529 women with diminished ovarian reserve and reported that CoQ10 pretreatment was associated with higher clinical pregnancy odds (odds ratio 1.84), lower miscarriage rate, fewer cycle cancellations, more oocytes retrieved, and reduced gonadotropin requirements. Shang and colleagues (Advances in Nutrition, 2024) analyzed 20 trials with 2,617 women across multiple antioxidants and reported that CoQ10 outperformed melatonin, myo-inositol, and vitamins for improving pregnancy rates, and that the benefit was most pronounced in women under 35 with diminished ovarian reserve.
Shang's dose-response subgroup analysis produced the most surprising finding. The optimal CoQ10 regimen for improving pregnancy rate was 30 mg per day for three months before the ovarian stimulation cycle, and lower doses outperformed higher doses in the subgroup comparison. This contradicts the standard supplement-industry assumption that more is better. Most commercial CoQ10 products are sold at 100 to 200 mg per serving, and higher-dose products at 400 mg and above are common. The Shang finding is a single meta-analysis conclusion and the dose-response question is not fully settled, but the direction is worth paying attention to. If the effect is real, it suggests that the limiting factor is duration of exposure, not plasma peak.
A few honest qualifications. Most of the clinical evidence is in women with diminished ovarian reserve or poor ovarian response, not in women with normal ovarian function, so the generalization to the broader population trying to conceive without assisted reproduction is less well established. Clinical pregnancy odds increased in the pooled meta-analysis, but the effect on live birth rate is less clear across individual trials. One trial (Micaraseth 2024, British Journal of Nutrition) found that two weeks of CoQ10 pretreatment did not protect AMH levels in women undergoing hysterectomy with salpingectomy, suggesting that short-duration pretreatment may not be sufficient for all indications. The 30 mg dose figure is from one meta-analysis subgroup and deserves replication before it becomes a firm recommendation.
What this adds up to. For women with diminished ovarian reserve undergoing IVF, the evidence for CoQ10 pretreatment is the strongest it has ever been, and the mechanism is unusually well-characterized for a supplement intervention. The reasonable regimen based on the current literature is CoQ10 at 100 to 200 mg per day for two to three months before a stimulation cycle, with the caveat that the Shang meta-analysis suggests lower doses at longer durations may be equally or more effective. The timing matters more than the peak dose. The biology it's acting on is specific, identifiable, and translatable from animal models to human IVF outcomes.
Ben-Meir et al., Aging Cell, 2015
Xu et al., Reproductive Biology and Endocrinology, 2018
Lin et al., Annals of Medicine, 2024
Shang et al., Advances in Nutrition, 2024
